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Abstrak: Sebuah survei yang menggunakan 68 pertanyaan melalui internet yang 
digunakan untuk menentukan dampak dari televised direct-to-consumer advertising 
(DTCA) pada konsumen yang diprakarsai perubahan pengobatan penyakit 
gastroesophageal reflux (GERD) dan sosial anxiety disorder (SAD). Dari 427 
responden, 10% pasien GERD yang melihat DTCA dan 6% pasien SAD yang 
melihat DTCA melaporkan bahwa mereka kemudian memulai percakapan dengan 
dokter mereka. Hampir setengah dari responden, 47,4% untuk GERD dan 40% 
untuk SAD, melaporkan bahwa perubahan dalam terapi terjadi sebagai akibat 
langsung dari diskusi dengan dokter. DTCA melalui televisi untuk kedua golongan 
obat dapat memiliki dampak yang signifikan pada pasien yang memulai dalam hal 
permintaan resep.Reaksi terhadap DCTA untuk obat resep memang beragam. 
Proponent berpendapat bahwa hal itu menyediakan konsumen dengan informasi 
tentang pilihan pengobatan, dan mungkin membantu untuk meningkatkan kesadaran 
masyarakat, dan akibatnya pengobatan, penyakit serius seperti diabetes, hipertensi, 
atau depresi. Di lain pihak,mereka juga khawatir bahwa DCTA  tidak tepat dapat 
meningkatkan permintaan pasien yang spesifik, dan umumnya mahal, agen, dan 
bahwa permintaan ini mungkin memiliki efek negatif pada praktek medis dan pada 
hubungan dokter-pasien. Isi iklan yang ditujukan untuk dokter telah diteliti, tetapi 
mereka ditujukan untuk pasien telah kurang mendapat perhatian. Tujuan penelitian 
ini adalah untuk membangun pesan  yang sedang diterima oleh masyarakat dari 
DCTA.  Berdasarkan sampel kecil, DTCA yang melalui televisi untuk obat yang 
digunakan untuk mengobati GERD dan SAD dapat memiliki dampak yang 
signifikan pada kedua pasien yang diprakarsai atas permintaan resep dan praktek 
resep dokter dan dapat mengakibatkan perubahan terapi untuk penyakit ini. 
 
Kata Kunci: DCTA, Perilaku Konsumen, Persepsi, Brand value 
 
Background 
The first direct-to-consumer advertisement for aprescription drug appeared in 
Reader’s Digest in 1981in USA. Over the next few years, other suchadvertisements 
were published, and the US Food andDrugs Administration (FDA) became worried 
thatlittle was known about the potential effect of suchadvertisements on the public. 
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Consequently, in 1983,the FDA initiated an advertising moratorium while itstudied 
the issues and considered the regulatoryoptions. Although they concluded that 
“direct tothe public prescription advertising was not in thepublic interest,” the FDA 
lifted the moratorium in1985 because of concerns about freedom of speechand a 
general consensus that regulations alreadyin place were sufficient to protect the 
consumer.After the moratorium had been lifted, directto-consumer advertising was 
permitted providedthat the advertisements met certain criteria;specifically, that they 
presented true and balancedinformation about the side-effects of the drugs,and their 
contraindications and effectiveness.The FDA monitors compliance with these 
criteria. 
However, prior approval of drug advertisements is notrequired.Reaction to 
direct-to-consumer advertisements forprescription drugs is mixed. Proponents argue 
that itprovides consumers with information about treatmentoptions, and might help 
to increase public awareness,and consequently treatment, of serious diseases suchas 
diabetes, hypertension, or depression. Opponents,however, are worried that direct-
to-consumeradvertisements might inappropriately increase patientdemand for 
specific, and generally costly, agents, andthat this demand might have a negative 
effect onmedical practice and on the physician-patientrelationship.Over the past few 
years, investment in direct-toconsumeradvertising in this field has risen, and 
nowexceeds US$1 billion Concurrently,many pharmaceutical companies have 
reduced theamount spent on direct-to-physician advertising,which suggests a tactical 
shift in their focus fromphysicians to patients. Last year, for example, 
drugcompanies spent more on advertisements innewspapers and popular magazines 
than they did inmedical journals ($685 million vs $473 million,respectively) 
(www.imshealth.com accessed on Aug25, 1999). 
The content of advertisements aimed atphysicians has been researched, but 
those aimedat patients has received less attention. Our aimwas to establish what 
messages are being receivedby the public from direct-to-consumeradvertisements. 
Although such advertisements forprescription drugs only appear in the USA 
andNew Zealand, the lessons drawn from theAmerican experience might be of 
relevance in theUK, where the debate over this type ofadvertisement is just 
beginning. 
Direct to consumer advertising (DTCA) of prescription medicines is a hotly 
debatedtopic: in the United States and New Zealand, the only countries where it is 
fullyallowed; as well as the European Community, Canada and Australia 
whereregulatory changes to ease current restrictions are being or have recently 
beenconsidered. Medicines agencies and governments in these countries are 
examiningand reporting on the issue frequently. Those governments that already 
allow DTCAhave continued its use, though with additional restrictions, after their 
most recentreviews (Meek, 2001a; Meek, 2001b). 
Direct-to-consumer advertising (DTCA) is a controversial topic among 
health careproviders, professional organizations, and pharmaceutical 
manufacturers.Advocates state that DTCA empowers patients with the information 
needed to morefirmly grasp control of their own health care decisions (Bonaccorso 
& Sturchio,2002; Calfee, 2007; Holmer, 1999, 2002) and helps patients initiate 
conversationswith their physicians about sensitive health topics that they otherwise 
may have beenunable to broach (Calfee, 2007; Donohue, 2006; Kravitz et al., 2005). 
On the otherhand, critics of DTCA say that it increases health care costs and leads to 
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conflictbetween the provider and the patient (Aikin, Swasy, & Braman, 2004; 
Kravitzet al., 2005; Mintzes et al., 2003; Robinson et al., 2004; Spence, Teleki, 
Cheetham,Schweitzer, & Millares, 2005; Weissman et al., 2004). The vast majority 
of governments have decided to ban or heavily regulate DTCA due to lack of 
evidence thatit is truly beneficial to the patient and other health care team members. 
Theirconcerns center around its potential as a catalyst for increased medication 
prescribingand health care costs, with the United States and New Zealand being the 
onlyexceptions to these stiff regulations (Auton, 2006; Brownfield, Berrnhardt, 
Phan,Williams, & Parker, 2004; Mintzes et al., 2002). 
 The billions of dollars that pharmaceuticalcompanies spend annually on 
advertising in the United States are staggering,with an increasing amount of the 
funds being designated for television campaigns(Rosenthal, Berndt, Donohue, 
Frank, & Epstein, 2002). In 2006, a total of 12 billionadvertising dollars were spent 
by the pharmaceutical industry, with 40% of that figureearmarked for DTCA (IMS 
Health, 2007). The drug companies typically concentratetheir advertising efforts on 
a select few patent-protected products that havemild side effects and are used to treat 
chronic health conditions that patients alreadymay feel comfortable self-treating 
(Findlay, 2002; Rosenthal et al., 2002; UnitedStates General Accounting Office 
[USGAO], 2002). Research has shown that theclasses of medications most heavily 
advertised are antidepressants, antihistamines(i.e., used to treat allergies), 
antihyperlipidemics (i.e., used to lower cholesterol),nasal sprays, and proton pump 
inhibitors (i.e., used to reduce gastric acid and treatcondition such as 
gastroesophageal reflux disease or GERD; Rosenthal et al., 2002). 
These five classes account for approximately 60% of all DTCA dollars 
spent(Rosenthal et al., 2002).One forward-thinking study conducted by Bell, 
Kravitz, and Wilkes in 1999used a phone survey of 329 California patients to 
measure the actual influence thatDTCA has on the patient–physician interaction. 
The authors found that 19% ofpatients had asked for a prescription as a result of 
viewing DTCA and 35% soughtmore information from their health care providers 
regarding a DTCA medication.This study did not attempt to determine or isolate the 
effect of any particular typeof DTCA the patient may have encountered, such as 
television, print, radio, orInternet.The influence of DTCA on the patient–physician 
relationship also was studiedby Mintzes and colleagues, who administered a patient–
physician paired survey to78 physicians and 1,431 patients in doctors’ offices in 
Sacramento, California, andVancouver, British Columbia, to capture data regarding 
the influence of DTCAon consumer behavior and its impact on physician 
prescribing (Mintzes et al.,2002; Mintzes et al., 2003). The authors reported that 
patients who requested aDTCA medication from their doctors were more likely to 
receive one or morenew prescriptions than those patients who did not discuss 
advertised medications(Mintzes et al., 2003). Of the 12% of respondents who 
actually requested a medicationfrom their physician, 42% of the requests were for an 
advertised medication(Mintzes et al., 2002). Again, this study, as well as several 
others (Datti & Carter,2006; Murray, Lo, Pollack, Donelan, & Lee, 2004; Robinson 
et al., 2004), did notfocus on televised DTCA exposure, but rather examined the 
influence of other typesof advertising viewed. 
To the best of the authors’ knowledge, this is the only study in the 
publishedliterature that conducted Internet-administered survey research to attempt 
topinpoint the effect of advertising specific to television. Television 
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advertisementviewing influences consumer behavior for products other than 
pharmaceuticals,and it is reasonable to assume that the average of 16 hours a year 
that consumersview televised DTCA is going to be influential on patient attitudes 
and behaviorsas well (Brownfield et al., 2004). This study endeavors to discover the 
specificinfluences of television DTCA and seeks insight from a targeted population 
byutilizing the Internet for data collection. 
The conclusions of these national agency reviews, as well as those by 
specialisedanalysts such as Barbara Mintzes from the University of British 
Columbia, is that theevidence for either the positive or negative effects of DTCA on 
health outcomes isinsufficient. Increases in medicines use are self-evident 
consequences ofadvertising. Interpretations of the limited studies on whether 
consumers and healthsystems benefit from this change are polarised. Indeed the 
New Zealand policyreview on DTCA reported to its Minister (Ministry of Health, 
2001): 
Despite concerns about the quality and interpretation of the evidence, there 
areareas where there is little disagreement between the parties. DTCA 
undoubtedlyincreases medicine enquiries by consumers to prescribers, and 
subsequentprescribing to consumers. It is more commonly used for high cost, 
newermedicines, targeted at long-term use by large populations (NIHCM, 1999, 
Rosenthalet al, 2002). It has met with limited enthusiasm from government, 
professionalsand consumers and been the subject of public controversy and 
governmentresponses in a number of instances involving questions of advertising 
standardsand/or safety (HAI, 2001a, b). 
DTCA usually occurs as a component of much wider scale, longer term and 
lessvisible marketing and public relations plans, involving the media, medical 
andcommunity opinion leaders, researchers and clinicians, community 
organisationsand patient groups (NIHCM, 2000, Rosenthal et al, 2002). Integrated 
marketingcampaigns involving components directed at professionals, consumers 
andpayers/formulary managers have been described as the way of the future 
(Scrip,2000). 
The movement to DTCA across many countries reflects 
internationalpharmaceutical companies responding to competitive pressure as both 
health careproduct providers, and important industry partners to governments. 
Discovery ofnew chemical entities has slowed and the requirement to maintain 
revenuesexpected of the industry has forced greater emphasis on ways to boost 
salesthrough marketing. The rise of consumerism is also cited as a factor, making 
itmore effective for patients to influence their doctors than in the past (Meek, 
2001,pp.4-6). DTCA may also be seen by pharmaceutical marketers as a way 
ofovercoming attempts by health care systems to limit doctors’ prescribing - by 
usingconsumers to drive demand (Pharmaceutical Marketing, 2001). 
A broader consideration of the DTCA policy context is also required. The 
transnationalnature of the industry is demonstrated in the current concerted 
effortacross many jurisdictions to reduce regulatory controls around advertising 
ofprescription medicines. Recent decisions by the European Union 
andrecommendations of a review in Australia now show similar direction of 
movement.The industry is also important to national economies: Charles Medawar 
hasdescribed the concern at high levels of government in Europe about a 
threatenedexodus of pharmaceutical companies to the USA, based on industry 
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claims of“external constraints and pressures” and “hostile” market conditions such 
astighter regulation, price controls and increased emphasis on drug evaluation 
(SocialAudit, 2002). 
The proponents and lobbyists for DTCA extend beyond health product and 
serviceproviders to include advertising agencies, public relations and media 
(includingmagazines, newspapers, radio and television) with obvious interest in 
thesubstantial expenditure and activity in advertising medicines. 
Advertisingstrategies currently being used in Australia are similar to those for other 
productssubject to advertising restriction or prohibition: creating indirect references 
to theproduct through general awareness campaigns by the product promoter; 
linkedmedia campaigns using print, television and the internet; the use of 
sponsorship;and creating associations between product packaging and marketing 
campaignimages and colours. 
Responses to DTCA in other countries reflect different aspects of 
Australia’scomprehensive approach to medicines policy. Proponents and 
opponents'arguments touch on safety and quality, access through direct and 
subsidised coststo consumers, judicious, safe and appropriate medicines use, and 
industryconsiderations. It is therefore important that the forms of DTCA in 
Australiacurrently occurring and proposed be considered within the National 
MedicinesPolicy framework. 
 
Objective 
The objective of this study is to determine the impact that DTCA has on 
consumerinitiatedmedication changes for the treatment of GERD and SAD. 
 
The Development of DTCA Across Countries 
The most comprehensive recent literature review on DTCA was conducted 
byBarbara Mintzes of the Health Policy Research Unit at the University of 
BritishColumbia (Mintzes 2001, Vol 2). Mintzes’ review of the literature forms part 
of alarger report funded by Health Canada of the health system impacts of DTCA. 
Thereport is publicly available on the University website.Mintzes’ review gives 
comprehensive analysis of the international evidence onDTCA, and charts its 
development in the United States and New Zealand (Mintzes2001 Vol 2. pp. 22-31). 
As these two countries represent the only fully developedmodels of DTCA, they 
illustrate many of the issues involved. They each show arapid rise in DTCA in a 
short period of time, boosted by regulatory relaxation.Public and professional 
concern in both countries has prompted ongoing inquiry andreview over twenty 
years, though with little new contribution to the evidencebase. 
It is important to note that in both the US and New Zealand, legislation has 
neverspecifically prohibited advertising prescription medicines to consumers. In 
each,take-up of the opportunity for DTCA has only occurred within the last twenty 
years.In both countries expenditure on DTCA and the number of products has 
acceleratedrapidly in recent years.United StatesDTC advertisements in the US can 
be classified into three types, useful for broadlyconsidering the scope of this form of 
advertising. “Help seeking” ads are ones inwhich people are alerted to a condition or 
disease, informed a treatment isavailable and encouraged to see their doctor. A 
company name can be used.“Reminder” ads give the name of the medicine, but not 
the disease or conditionand are designed to build brand name recognition. “Product 
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claim” ads name abrand and its intended use and, unlike the other categories must 
meet morestringent requirements for presentation, summaries of information and 
contacts forfurther information (NIHCM, 2000, p.14).In the US, only one 
prescription medicine was being advertised in 1981; by 1989, 21companies were 
advertising 30 products. Throughout that decade DTCA wasprincipally about 
disease states and did not mention specific product names(Mintzes 2001 Vol 2. pp. 
22-31).An early DTCA campaign for benoxaprofen led to 500,000 prescriptions in a 
fewmonths. The product was subsequently withdrawn following deaths from 
liverfailure, prompting the US Food and Drug Administration to call a 
voluntarymoratorium in 1983 to research DTCA and any legislative options 
required. Theadvertisements were already subject to regulatory action because 
ofunsubstantiated claims for its use in the treatment of arthritis (Mintzes 2001 Vol 
2.p.7). 
At a 1984 FDA symposium on DTCA the head of the Drug Advertising 
Branch statedthat the major conclusions of the symposium were that virtually no-
one was infavour of DTCA, it would serve no educational purpose and would be 
veryexpensive. Despite this, it was seen as inevitable and driven by the 
vestedinterests of advertising agencies (Mintzes 2001 Vol 2. p.8).Even members of 
the US pharmaceutical industry were opposed to DTCA in 1984.At one industry 
symposium, 80% of executives were opposed, based on concernsabout product 
liability, increased costs of marketing and lower profitability. Oneindustry director 
noted that if companies thought their product was appropriate forOTC type 
marketing, they should apply for it to have OTC status (Mintzes 2001 Vol2. p.7). 
The FDA moratorium ended in 1985, without any new or changed 
legislation. It wasconsidered that DTCA could be regulated in the same way as 
advertising to healthprofessionals. Total expenditure on DCTA grew from US$35M 
in 1987 to US$695M in1996, with nearly 80 products being advertised by that time 
(Mintzes 2001 Vol 2.p.8). 
In 1995 the FDA held further consultations, in an environment where 
industry wasnow much more supportive and active in using DTCA. A key 
regulatory identified by industry by that time was the requirement for a summary of 
labellinginformation to be included in “product claim” advertising, which made 
TVadvertising difficult. Most had got around this requirement by only 
using“reminder” ads, which mention the product name, but make no health claims. 
Theregulatory basis was that these were allowed in advertising to health 
professionals,however FDA noted that consumers found such ads unclear about 
what conditionthe product treated (Mintzes 2001 Vol 2. pp. 8-9). 
In 1997, the FDA issued a draft guidance, removing the requirement for 
thelabelling summary, and replacing it with a statement of the product's major 
risksand providing sources of further information including toll free numbers, 
websitesand simultaneous print DTC ads in doctors offices, libraries and stores 
(Mintzes2001 Vol 2. p.9). 
This change led to further growth in DTCA with a move in expenditure 
totelevision; the growth in total DTCA expenditure accelerated to over US$1.1 
billionin 1998 and $US2.5 billion in the year 2000 (NIHCM, 2000, p.3). In 2000 
itaccounted for just under 16% of total spending on promotion (Rosenthal et 
al,2002). US television viewers are reportedly exposed to an average of nine 
DTCAslots a day (Lancet, 2002).The evidence shows a move to “reminder” and 
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“product claim” advertisementsrather than “help seeking” ads as regulation has 
relaxed. Of the total spent onDTCA in 2000 in the United States, 85% was spent on 
brand name advertising, whilethe remainder was spent on disease state advertising 
(NIHCM, 2000, p.11).New ZealandMintzes’ review shows New Zealand 
experienced growth in DTCA similar to the USin the short period from its beginning 
circa 1995. Only 10 products were advertisedin the period 1996 –1999, but 46 were 
advertised in the period 1999 –2000 (Mintzes2001 Vol 2. pp. 22-31). 
A major concern in New Zealand has been the direct to consumer 
advertising ofsubsidised medicines with consequent impacts on demand and costs. 
Pharmac, theagency responsible for subsided medicines, noted that 20 of the 
productsadvertised in 1999-2000 were in this category. Attempts to ban DTCA of 
subsidisedmedicines were unsuccessful.Public concern about the campaign for 
orlistat (a medicine for weight loss) led to apolicy review in 2000-01; additional 
concerns were raised when an asthmamedication (montelukast) was promoted with 
an offer of one month’s freemedication (thereafter the cost to the consumer being 
$118 per month). A currentanti-smoking medicine campaign offers to pay for the 
first visit to the GP (personalcommunication, 2002).Pharmac expressed major 
concerns to the policy review in which it called for DTCAto be banned (Mintzes 
2001 Vol 2. pp. 22-31).  
The New Zealand Ministry of Health discussion paper canvassed the 
arguments forand against DTCA and proposed 4 policy options, from the industry 
self regulatingstatus quo to a complete ban (Ministry of Health 2000).The discussion 
paper argued “for” and against” cases about DTCA, that it: 
• Improves/does not improve some people’s access to information 
• Raises/does not raise fiscal pressures 
• Damages/preserves-enhances the doctor-patient relationship 
• Encourages/does not encourage medicalisation. 
Despite the history of DTCA and obvious concern among stakeholders, the 
reviewpaper noted that evidence to support these arguments was limited, and this 
wasconfirmed in the subsequent policy advice to the Minister (Ministry of 
Health,2001). The decision of the NZ Government after this review was to retain 
DTCAbut introduce some new restrictions, for example, on pharmaceutical 
companysponsorship of events (Ministry of Health, 2001). 
In December 2003 the Australian and New Zealand governments signed a 
treaty tocreate a single agency regulating the registration and promotion of 
drugs,complementary health products, and medical devices. While this will still 
allow forAustralia and New Zealand to maintain different policies on DTCA of 
prescriptionmedicines, the New Zealand Minister for Health was reported in early 
2004 to beseeking approval from the New Zealand cabinet for the adoption of 
commonstandards with Australia on the marketing of medicines, as a way of 
instituting aban on advertising prescription-only drugs directly to consumers 
(Burton, 2004).Work in Australia and New Zealand is now (April 2004) well 
progressed for thedevelopment of a single Trans-Tasman regulatory authority to 
replace theTherapeutic Goods Administration and a new Trans-Tasman advertising 
code toreplace the Australian Therapeutic Goods Advertising Code. PHARM has 
providedinput to these initiatives and supported the proposed maintenance of 
existing lawscovering DTCA in Australia. 
 
Influence on Consumer…                                                                                   Budi... 
 112 
The European Community 
The introduction of DTCA was under active consideration in Europe in 2002. It 
wasproposed that DTCA be allowed in relation to drugs for three conditions for a 
fiveyearperiod after which a review will occur. Reports from the EC were 
conflictingabout whether the trial would allow DTCA by companies only in 
response torequests from patients, or whether it would allow broader advertising 
(HAI, 2002). 
In October 2002 the European Parliament rejected the proposal.As in 
Australia, more indirect forms of promotion, such as disease awarenesscampaigns, 
have been a feature of the European scene for some time. 
 
Canada 
In Canada regulations permit some forms of DTCA – disease awareness 
advertisingthat does not mention a product, and advertisements that mention the 
productname but not the condition for which it is used. However, many Canadians 
areroutinely exposed to DTCA as much of the cable and satellite television access is 
toUS stations, governed by US regulations. 
 
DTCA in the Australian context 
Australia differs from each of the other jurisdictions in having a 
comprehensiveNational Medicines Policy (NMP) (Commonwealth of Australia, 
2000). The NMPmandates consideration of quality use and equitable access, as well 
as themaintenance of a responsible and viable pharmaceutical industry; providing 
anopportunity for partnership approaches to DTCA with a goal of maximising 
benefitsand minimising harm for all stakeholders. The framework of the NMP also 
providesa useful environment for testing the outcomes of medicines promotion 
forgovernment, industry, providers and consumers.DTCA also has a major bearing 
on another arm of the NMP – access to affordablemedicines – to the extent that it 
increases demand for new expensive medicinesthus putting additional pressure on 
the viability of the PBS and/or some consumers'ability to afford higher co-
payments.Much of the claim for DTCA is about harnessing the obvious commercial 
selfinterestand technical knowledge of the company in the service of improved 
QUMthrough better-informed consumers (Bonaccorso and Sturchio, 2002). Much of 
thecounter-claim is about potentially poorer use of medicines through 
medicalisationand lack of awareness of the full range of products available. 
Carefully designedstudies within comprehensive analysis of the marketing campaign 
and consumerresponses would assist in determining effects and ensuring efforts are 
directed tothe best possible outcomes for all stakeholders. 
 
The Current State of DTCA in Australia 
Advertising of medicines is governed by the Therapeutic Goods Act and 
twoindustry codes of practice: the co-regulatory Therapeutic Goods Advertising 
Codewhich covers promotion to the public of over-the-counter and 
complementarymedicines, and the self regulatory Medicines Australia Code of 
Conduct. The lattercontains a section on Communications with the Public, which 
covers such mattersas media statements, general media articles and patient education 
(MedicinesAustralia 2003).In January 2003, a new edition of Medicines Australia’s 
Code of Conduct becameeffective. In relation to communications with the public, it 
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contains new clausescovering media releases about named prescription products and 
about companyinvolvement in patient support programs.In December 2003, the 
Australian Competition and Consumer Commission grantedauthorisation of Edition 
14 of the Code subject to conditions requiring MedicinesAustralia to: 
• Undertake greater monitoring of pharmaceutical company promotionalactivities; 
and 
• Publish full details of all breaches of the Code on its website (ACCC, 2003). 
In 2001 the Review of Drugs Poisons and Controlled Substances Legislation 
usefullydescribed the purpose of requiring a prescription for a medicine (Galbally, 
2001.p.37): 
 
By requiring that a prescription be obtained for the medicine, the intention isto 
overcome the consumers’ lack of knowledge and understanding to:• Diagnose the 
condition from which he or she is suffering; 
• Determine the most appropriate treatment; and 
• Use the product safely and effectively. 
 
Galbally notes that restrictions on advertising “… are not intended to 
depriveconsumers of information about medicines …”. They incorporate the 
provision ofinformation through a ‘learned intermediary’: the doctor and 
pharmacist(Galbally, 2001. p.87). The Review notes later that arguments for DTCA 
are basedon the assumption that doctors will act as a “… perfect gatekeeper (with) 
up-todateknowledge, a capacity to evaluate promotional material and to 
communicateabout the treatment with patients” (Galbally, 2001. p.90). 
Despite the existence of laws at State, Territory and Commonwealth level 
thatexplicitly prohibit any person publishing an advertisement about a 
prescriptionmedicine, the Review noted these limits were being tested in 2001: 
 
A number of advertisements highlighting a disease state withoutmentioning a 
product or the company that sponsored the advertisementshave been brought to the 
Review’s attention. The advertisements andsurrounding public relations activities 
have ensured that most people wereaware which product was being advertised. The 
advertisements did notbreach the advertising regulations and the industry 
association was unableto deal effectively with the situation particularly where the 
companieswere not members of the association. 
 
Citing this and other concerns to stakeholders, the Review concluded that 
selfregulationor co-regulation of the advertising of prescription medicines using 
acode of practice would be unlikely to achieve the necessary controls. However, 
itproposed allowing government to solicit advertisements as part of a disease 
stateeducation strategy and to allow advertising of prices, the distribution of 
ConsumerMedicine Information and disease state advertisements according to codes 
ofpractice, with adequate safeguards to prevent unscrupulous suppliers exploitingthe 
advertisements (Galbally, 2001. p.92-3). 
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DTCA and QUM 
DTCA and judicious use, including the consideration of non-medicine 
optionsDTCA may promote the use of medicines more prominently than non-
medicinealternatives. The evidence based on expenditure and market development 
alone isthat DTCA works in promoting demand. Indeed, it has been described as 
“thewonder drug for the pharmaceutical industry itself” because of its ability to 
affectpatient demand and, in turn, prescribers’ behaviour (Hoffman and Wilkes, 
1999).Mintzes notes that well designed studies of information content in DTCA 
have foundtheir information quality to be poor, with factual inaccuracies and 
inadequatebalance of benefit and risk information. Over half of the 1998 US 
broadcast adsviolated US regulations (Mintzes 2001 Vol 2. p.iv).US pharmaceutical 
consulting firm Scott-Levin has described the effect of brandadvertising. It reported 
in 1998 that visits to doctors for heavily advertisedconditions rose 11% compared to 
a 2% increase in total office visits in the periodJanuary and September. Visits for 
high cholesterol rose 26% (Scott-Levin 1998b).In another release by the same 
company, a spokesman reported: 
 
“DTC is not only raising consumer awareness of available treatmentoptions, it is 
driving patients to their physicians to further discuss theseoptions, with these same 
patients frequently requesting a specificmedication by name. Physicians are also 
honouring these drug requests”. 
 
The research showed requests for loratidine (antihistamine) were honoured 
86% ofthe time and for pravastatin (lipid lowering) 93% of the time (Scott-Levin, 
1998c).Mintzes has identified and analysed 22 consumer surveys on DTCA reported 
in theperiod 1991-2001. While there are considerable variations and limitations 
insample and methodology, a number of findings are suggested by this 
evidence(Mintzes 2001, Vol 2. pp.32–52).In US random sample surveys, DTCA 
prompted between 20 and 30 percent ofconsumers to speak to their doctor about a 
medicine. Up to 10% of these directlyrequested a medicine and over 80% of these 
received it. Up to half of theconsumers in one survey indicated they would switch 
doctors if they did notreceive a prescription they requested.This may be a particular 
concern under the Galbally proposals (Galbally, 2001.p.93), where government is 
encouraged to solicit advertising from companies aspart of disease state advertising. 
Consumers’ capacity to choose based on normalsources of objective information 
may be severely compromised where multiplesources of information are mobilised, 
coordinated and resourced by thepharmaceutical company. 
There is concern about the ‘medicalisation’ of minor or self-limiting 
conditions as aproduct marketing strategy (Moynihan, Heath and Henry, 2002). This 
involvescoopting medical and consumer advocates in large-scale strategies to 
promote thesponsors’ medicine for an otherwise “under-treated” condition. In this 
instanceDTCA can promote large-scale uptake of medicines that would otherwise be 
usedsparingly, if at all. It leads to the development of new health expenditures 
byconsumers, governments or both. 
DTCA and appropriate selection, when a medicine is chosen as the best 
therapyMintzes notes one report by PHARMAC in New Zealand, where brand 
promotion of asteroid inhaler for asthma (fluticasone) was associated with 
substitution of thisproduct for a less expensive but therapeutically equivalent 
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beclomethasoneinhalers (Mintzes 2001, Vol 2. p. vi).The availability of Consumer 
Medicines Information (CMI) as approved objectiveinformation about a medicine 
may assist appropriate use. However, interpretationof the CMI is envisaged to take 
place in consultation with an independent “learnedintermediary” and in an 
environment of peer and community support based onobjective evidence.CMI 
cannot assist appropriate selection by consumers as it is product specific anddoes not 
provide comparative drug information. DTCA is also product specific. Thefull range 
of therapies available are not all advertised, with bias towards newerand more 
expensive therapies. DTCA is unlikely to provide consumers withobjective 
comparative drug information to assist them with appropriate selection. 
There also may be risks from overuse of medicines and/or sharing resulting 
fromDTCA, given the persuasive and credible nature of advertising, the limited 
brandmarketing objective and the risk of consumers not pursuing or finding 
sufficientobjective information through other channels.DTCA and safe and effective 
useA significant consideration in DTCA in the Australian context is the role of 
thescheduling of medicines. Galbally notes that scheduling reflects the level 
ofprofessional advice and counselling necessary to overcome the 
informationasymmetry between the consumer and sponsor of the product. The level 
ofrestriction is based on the hazardous properties of the substances and the 
risksassociated with supplying and using products containing them (Galbally, 
2001.p.33). 
A consistent finding across the US surveys on DTCA and replicated in New 
Zealand isthat consumers regard the existence of medicine advertisements as an 
indication ofgovernment-approved safety and low risk. A 1999 FDA survey found 
that more thanhalf of the respondents could not explain what prescription-only 
meant and onequarter thought that only the safest medicines could be advertised to 
the public.Galbally (2O01) considered that there was enough anecdotal evidence to 
concludethat at least some consumers equate advertising with safety and this creates 
”particularly risk-laden situation” especially where the provider fails to 
providenecessary counselling and CMI (p.90). 
Similarly, there are consistent survey findings that consumers overestimate 
thequality and scope of information in DTCA. For example, a New Zealand survey 
ofwomen assessed their responses to an advertisement for Cyproterone. Forty-
fivepercent thought the ad gave them enough information on whether to take 
themedicine and 27% thought it clearly stated the risks and benefits. The only risk 
statement was: 
 
“Diane-35 has a similar side effect profile to other oral contraceptives.Some women 
should not use Diane-35”. 
 
Cyproterone is associated with serious risk for liver toxicity, 
higherthromboembolic risks than other oral contraceptives and has been restricted 
fromuse as a contraceptive in Europe. A coplaint about the advertisement 
wassubsequently upheld.“Prevention” magazine surveys in the US in 1998 and 1999 
found that whilerespondents were increasingly aware of the advertisements, many 
were unaware ofwhat conditions they treat. Mintzes notes (2000, v.2 p.39): 
Most people who were aware of ads for a drug and had the conditionremained 
unaware of the drug’s indication. These results suggest that inmany cases DTCA is 
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more successful in stimulating brand recognition thanin conveying information 
about conditions for use such as the drug’sindication. 
 
There have been several instances of extensive DTCA and promotion 
leading tosignificant uptake by consumers, with subsequent concerns about 
and/orwithdrawal of the medicine (HAI, 2001b; Mintzes 2001, Vol 2. pp.32–52)). 
This maybe a particular problem without good adverse event reporting and in a 
regulatoryenvironment where fast track processes enable market availability without 
fullsafety data.DTCA as a contributor to medicines educationEducation and 
information is an essential part of the National Medicines Policy andin particular the 
Quality Use of Medicines. Industry is an important contributor toresearch and 
development, professional and consumer education and information.It benefits from 
appropriate use, through the capacity to enhance markets andprofitability through 
addressing under-use and in reduced product liability(National Medicines Policy 
2000, p.7). 
 
A typical statement of the educational claims for DTCA is a quote from a 
VicePresident of Marketing for Zeneca Pharmaceuticals: 
 
DTCA allows ethical pharmaceutical companies to educate patients on therange of 
options that are available to help them manage their diseasestates. Since companies 
are expected to and in fact should always promotethe safe use of products, 
education should provide the foundation for theoverall communication programme. 
(In Meek, 2001, p.19) 
 
As noted earlier, well-designed studies of information content in DTCA 
have foundtheir information quality to be poor with factual inaccuracies and 
inadequatebalance of benefit and risk information (Mintzes 2001 Vol 2. p.iv).In 
discussing the question of whether DTCA improves consumer access toinformation, 
the New Zealand Ministry of Health discussion paper noted that theirmedicines 
agency MedSafe found just 33% compliance with DTCA regulation byprescription 
medicines advertisements in 1998 and only two thirds compliance in1999 (Ministry 
of Health 2000). The discussion paper comments: 
 
The record of the industry in New Zealand has caused concern. Medsafe’sFebruary 
2000 examination of non-compliance suggests that the status quoDTCA position is 
unlikely to guarantee a medicines advertising environmentthat, on balance, will 
provide either net health benefits or, at least, anabsence of net health costs in terms 
of information transfer. 
 
This comment, similar to that of Galbally about the capacity for regulation 
ofadvertising by the industry in Australia (Galbally, 2001. p.92-3), raises 
questionsabout how pharmaceutical companies perform in publicly agreed education 
andinformation partnerships with other stakeholders.Medicines education as a 
vehicle for DTCADirect-to-consumer advertising is just one channel in the 
marketing mix formedicines and typically occurs together with marketing to doctors 
and samplegiveaways (National Institute for Healthcare Management, 2000, p.5). 
Ultimately,consumers pay for medicines promotion (Hoffman and Wilkes, 1999). In 
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the US in2000, DTCA at US$2.6 billion added to the US$4 billion spent on 
physician officedetailing and over US$8 billion retail value spent on samples 
(NIHCM, 2000, p.4). 
DTCA has raised significant concern among professionals. Over half of 
USphysicians surveyed by the pharmaceutical consulting company Scott-Levin in 
1998said their attitude to DTCA was negative. More than half disagreed that DTCA 
“is areliable source of information; over 60% disagreed with the statement “DTC 
givesthe public information it can’t get anywhere else” and “it’s an objective source 
ofinformation” (Scott-Levin, 1998a).Australia also provides a number of avenues 
for medicines promotion, informationand education, including advertising to 
prescribers in professional journals,sponsorship of professional organisations, events 
and meetings, medicines detailingto doctors by company sales representatives and 
the provision of free “samples”through that representative system. It is also now 
commonplace to use medialaunches for promotion to the public through news and 
current affairs publications;and direct to consumer advertising such as the unbranded 
examples cited byGalbally above, with links to internet sites, patient groups and 
further productinformation. 
A Cochrane review shows that mass media approaches influence health 
servicesutilisation and can have an important role in both encouraging the use of 
effectiveservices and discouraging those of unproven effectiveness. The reviewers 
statethat the evidence supports the importance of ensuring that reporting in the 
laymedia correctly represents best available knowledge (Grilli R et al, 2002). 
Medicines Australia’s Code of Conduct says that promotion in patient 
associationpublications is regarded as promotion to the public, but does not cover 
otherrelationships with and sponsorship of patient support groups. The 
ConsumersHealth Forum has guidelines for consumer organisations about industry 
funding ofconsumer education and a group of companies has similarly developed 
guidelinesfor partnerships with consumer organisations (CHF, 2001, Tasker et al 
2002).Neither has any formal status at present.Concerns have been raised in 
Australia about both the primary motivation andmethods used in several examples 
of such campaigns by pharmaceuticalcompanies. Campaigns for medicines use in 
baldness, irritable bowel syndrome,social phobia, osteoporosis and erectile 
dysfunction have been shown to usesophisticated marketing and promotion plans 
involving raising awareness of thecondition and their product through the cooption 
of medical opinion leaders,distribution of background media stories, development of 
foundations and lobbygroups. Much of this activity includes promotional and 
monetary incentives forparticipants such as grants, donations, meetings, conferences 
and prizes(Moynihan, Heath and Henry, 2002).Moynihan et al suggest that such 
campaigns skew appropriate consideration oftreatment options: 
 
… within many disease categories, informal alliances have emerged,comprising 
drug company staff, doctors and consumer groups. Ostensiblyengaged in raising 
public awareness about under diagnosed and undertreated problems, these alliances 
tend to promote a view of theirparticular condition as widespread, serious and 
treatable. Because these“disease awareness” campaigns are commonly linked to 
companies’marketing strategies, they operate to expand markets for 
newpharmaceutical products. Alternative approaches … are played down 
orignored. 
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DTCA proponents argue that advertising is just one channel in a variety 
ofinformation available to consumers (Bonaccorso and Sturchio 2002): 
 
… consumers and patients are already inundated with myriad sources ofhealth 
information. The real question is how to ensure that people haveaccess to the best 
quality of information they need, when they need it.Direct to consumer advertising is 
just one channel by which healthinformation reaches consumers. 
 
However, the comprehensive marketing approaches described above are 
ones inwhich many channels of information are influenced by the 
pharmaceuticalcompany, including sources known to strongly affect consumer 
behaviour: media,professional opinion leaders and the learned intermediary required 
by regulation,the prescriber. When other sources of information such as charitable, 
communityand consumer organisations are also recruited as part of the promotional 
goal, thechannels available to the consumer seeking balanced and objective 
informationmay be further reduced.This has implications for Galbally’s proposal 
whereby government actually solicitsDTCA for disease state campaigns (Galbally, 
2001. p.93). Governments’ motives inmedicines policy have been called into 
question by industry who note that costcontainmentmay be a primary motivating 
factor, as with any payer (Bonaccorsoand Sturchio 2002). However Australia’s 
National Medicines Policy also reflects acommitment to achieving optimal health 
outcomes as well as economic objectives(National Medicines Policy, 2000. p.1). 
 
 
 
DTCA and the Internet 
The Internet is becoming increasingly important as a source of health 
informationand, judging by the extent it is being used for this purpose, it is also 
responding toa huge unmet desire for health information among consumers. In the 
US, it hasvariously been estimated that between 57% and 75% of Internet users have 
used itto obtain health information (Pew Internet and American Life Project 2000). 
Also,that 5% of people who use the Internet on a typical day use it to find 
healthinformation and 25% of searches through search engines involve health 
relatedissues. About 41% of Americans polled say that material they found on their 
mostrecent online health search affected decisions about whether they should go to 
thedoctor, how to treat an illness or how to question a doctor.In Australia the 
Therapeutic Goods Advertising Code governs advertising on theInternet of 
complementary medicines and OTCs directed at Australian consumers.Advertising 
to Australian consumers of prescription products through the Internetwould breach 
the Medicines Australia Code of Conduct. However, internationalaccessibility to 
overseas-based Internet sites means that Australian consumersreceive DTCA from 
these sources. 
A US study found that the majority of consumers feel it is difficult to 
distinguishbetween commercial and independent sites, identify the source of 
onlineinformation or determine whether the information has been reviewed or 
approvedby experts (Internet Healthcare Coalition 2000). Again, Australian 
consumers arelikely to face similar difficulties.In February 2004, Australia and the 
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United States completed negotiations on a FreeTrade Agreement (FTA) between the 
two countries. Medicines are a component ofthe draft agreement (Department of 
Foreign Affairs and Trade, 2004). In draftannexure 2-C, Clause 6 reads: 
 
Dissemination of Information.Each Party shall permit a pharmaceutical 
manufacturer to disseminate tohealth professionals and consumers via the 
manufacturer’s Internet siteregistered in the territory of a Party, and on other 
Internet sites registeredin the territory of a Party linked to that site, truthful and not 
misleadinginformation regarding its pharmaceuticals that are approved for sale in 
theParty’s territory as is permitted under each Party’s laws, regulations 
andprocedures, provided that the information includes a balance of risks 
andbenefits and encompasses all indications for which the party’s 
competentregulatory authorities have approve the marketing of the 
pharmaceuticals. 
 
This clause has led to some discussion about whether this would allow 
DTCA inAustralia. Australian officials’ advice is that the phrase “as is permitted 
undereach Party’s laws, regulations and procedures” ensures that current 
Australian lawprohibiting DTCA will apply. In addition a statement from Medicines 
Australia(2004) on this concern regarding the FTA states: 
 
The FTA text articulates that any marketing and advertising to consumersmust 
comply with existing laws. Current Australian law stands thatadvertising direct to 
consumers by industry is prohibited. The prescriptionmedicines industry accepts and 
supports this Government legislation. It isnot seeking to have this law overturned. 
 
DTCA in NESB communities 
When considering the current and potential impact of DTCA, the 
multiculturalnature of Australian society must be take into account. In the 1996 
Census, 41.1%of the total Australian population had at least one parent born 
overseas, and 13.3%had been born in a Non English speaking (NES) country. 
Australians speak 193languages and 15.1 % speak a language other than English at 
home (MulticulturalAffairs Unit, 1997: fact file 5). The cultural and linguistic 
diversity of Australia’spopulation is associated with certain challenges in relation to 
the use of medicines.First, the use of medicines is associated with various cultural 
beliefs and practices.Second, language barriers limit access to health information 
and health servicesespecially for recent arrivals.There is no research or other 
material that addresses issues with regard to DTCA toconsumers from NESB. It is 
evident that there is both a lack of and a great needfor culturally and linguistically 
appropriate information about medicines and theiruse. Ethnic media are important 
sources of health information among various NESBcommunities (NSW 
Multicultural Health Communication Service, 1999).Recently, the private sector has 
shown interest in the ‘ethnic market’ andmulticultural advertising and marketing 
flourish (Department of Immigration andMulticultural Affairs, 1997). There are 
about 110 newspapers and magazinespublished in 31 languages as well as various 
ethnic radio and television programsincluding SBS and community programs.The 
ethnic press is often privately owned and published on a shoestring budget,therefore 
financial benefits from possible DTCA could be welcomed by the ethnicpress.The 
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ethnic media does constitute an important means of delivery of healthinformation to 
various NESB communities and as such might attract attention ofpharmaceutical 
manufacturers in the case of the legalization of DTCA. While itmay have some 
attractions as a way of addressing the information deficit amongNESB consumers, 
the benefits of the ‘information’ provided by such advertisingwould be somewhat 
questionable as noted earlier. 
 
In summary, DTCA raises a number of concerns when considered from 
theperspective of the Quality Use of Medicines and the National Medicines Policy. 
1. There is clear evidence that DTCA increases consumer demand 
formedicines from prescribers, and that prescribing of the 
advertisedmedicines increases as a consequence. This is the obvious and 
intendedoutcome of DTCA. 
2. Extensive prescribing of newer medicines as a result of DTCA overseas 
hasled to significant problems in cases where the medicine is 
subsequentlyfound to have serious side effects or adverse consequences for 
health. Thisraises important public health considerations as well as 
questions of liabilityfor medicines’ promoters. 
3. DTCA strategies frequently overstate medicines’ benefits and minimise 
risksand side effects. This may undermine the judicious use of medicines 
andthe consideration of non-medicine options, and the ability to 
makecomparative choices where a medicine is deemed appropriate. 
4. While DTCA is prohibited in Australia, its use is growing and the current 
selfregulatoryindustry Code of Conduct has been unable to prevent 
thisoccurring. Australia should not allow DTCA to become established 
bydefault, given the major impacts evident in overseas jurisdictions. 
5. DTCA is being directed to subsidised as well as non-subsided 
prescriptionmedicines, with obvious implications for the Pharmaceutical 
BenefitsScheme. 
6. The proponents of DTCA extend beyond the medicines’ producers, 
toinclude advertising, public relations and media companies who stand 
tobenefit significantly from this expenditure. There is a potential conflict 
ofinterest between the media’s role as a public information provider and 
itsrole as a vehicle for advertising and promotion. 
7. DTCA occurs as part of more comprehensive marketing strategies 
directedto the media, prescribers, medical and health experts. 
Communityorganisations are increasingly being engaged in such campaigns 
and someappear to be set up by pharmaceutical companies for this purpose. 
8. The effect of such comprehensive and indirect marketing means 
thatconsumers’ capacity to obtain independent advice on medicines is 
limitedand they may be unaware of these influences on apparently 
independentsources such as prescribers, the media or community 
organisations. 
9. Government engagement in pharmaceutical company sponsored 
awarenesscampaigns may further reduce the availability of independent 
informationto consumers. 
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Consumers Perception, Value and Price 
Key intangibles assets such as brand value (or brand equity), product 
diffferentiation, and goodwill are the outcomes of investment in advertising. It’s 
generally believed that advertising contributes to the creation of brand value. Mizik 
and Jacobson (2003) argue that brand based advertising can create a comparative 
advantage for firms through its ability to differentiate the firm’s product. The brand 
can be a formidable barrier to imitation, as brand equity is difficult for competitors 
to copy, becoming an effective entry deterrence strategy. Industry observers and 
analysts note that many companies continue to emphazise brand building activities. 
While brand value creation is generaaly regarded as a “good thing”, we need to have 
more concrete measures of brand appropriation (i.e. extracting profits from brand 
value). Merely knowing the effect of brand value on purchase intent (Cobb-
Walgren, Ruble, and Donthu 1995) is inadequate; rather we need to understand the 
financial consequences of brand value (Chu and Keh 2006; Mizik and Jacobson 
2003). According to Keller, “To practicing managers, it is especially important to 
develop better measures that are able to directly relate marketing activity to actual 
performance”. 
There has been a steady stream of reserach studying the financial impact of 
advertising and brand value. Specifically, prior studies examine the 
contemporaneous association between advertising expenses and accounting and 
stock market returns (Erickson and Jacobson, 1992), advertising expenses and 
market value of the firm (Chauvin and Hirschey 1993), advertising and perceived 
quality (Moorthy and Zhao 2000), perceived quality and firm value (Aaker and 
Jacobson 1994), brand attitude and firm value (Aaker and Jacobson 2001), branding 
strategy and firm value (Rao, Agarwal, and Dahlhoff 2004), and brand value and 
firm value (Barth et al, 1998; Kerin and Sethuraman 1998; Simon and Sullivan 
1993). 
There are two issues about advertising. First, it has been shown that 
advertising has an important pass-through effect on branding. Advertising influence 
value creation in a firm by acting as an appropriation mechanism to build brand 
names and erect market barriers deterring competitor entry. The key role of 
advertising in a firm’s communication strategy in creating brand equity is realized 
through the promotion of ideas, goods, or services. In a practical sense, brand equity 
represents the added value the product garners as a result of past investment in the 
marketing activity for a brand. Despite the argument for this relationship, however, 
to date the literature has not explicitly examined the joint effects of advertising and 
brand value of firm performance.  
Second, firms spend large amounts annually on advertising and brand value 
creation with the expectation of reaping returns in the future. As such, it is important 
to examine not only the contemporaneous effect of advertising or brand value on 
firm performance, but also their lagged effects. 
The information value of advertising and brand value 
According to Low and Mohr: “ To be sure, advertising is vital to brand equity. 
However, advertising, per se, is not sacre cow that should necessarily be part of 
every year’s marketing allocation. Monies should be allocated to advertising only if 
it has a clearly defined role within that year’s strategy for meeting a brand’s goal”. 
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There have been numerous tudies, hovewer, on individual effect of 
advertising on the persistence of profits (e.g Mueller 1990), implying that excess 
returns erode more slowly for firms that advertise heavily. For example, Chauvin 
and Hirschey (1993) provide evidence that advertising expense has a positive 
influence on the market value of the firm. They suggest that spending on advertising 
can be viewed as a form of investment in intangible assets with positive effects on 
future cash flows. When Erickson and Jacobson (1992) control for endogeneity 
between discretionary expenditures and profitability, however, they find that 
advertising generates substantially lower accounting and stcok market returns than 
indicated in previous research. In a recent study Chu and Keh (2006) investigate the 
effect of advertising, promotion and RnD expenses on brand value creation. They 
find that these lagged expenses yield diminishing returns to brand value. 
Barth et al. (1998) examine the association between Financial World 
magazine’s brand value estimates and equity share prices of firms owning the 
brands. They estimate the association between the brand value estimates and share 
prices, controlling for equity book value and net income. They also estimate the 
association between year-to-year changes in brand value estimates and annual share 
returns, controlling for net income and change in net income. They find that brand 
value estimate provide significant explanatory power for share prices incremental to 
advertising expense, operating margin, growth, and market share. Brand value 
estimates are also significantly positively related to share prices after controlling for 
recognized brand assets and analyst’ earnings forecasts. 
Prior research has also examined the effects of perceived quality, brand 
attitude, consumer attitude and brand value estimates on contemporaneous return or 
market value (Barth et al 1998; Kerin and Sethurahman 1998). 
 
The Concept of perceived quality 
Quality can be defined broadly as superiority or excellence. By extension, perceived 
quality can be defined as the consumer judgement about a product’s overall 
excellence or superiority. 
Perceived quality is 
• Different from objective or actual quality. 
• A higher level abstraction rather than a specific attribute of a product. 
• A global assessment that in some cases resembles attitude 
• A judgement usually made within a consumer’s evoked set 
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The concepts of perceived price 
From the costumer’s perspective, price is what is given up or sacrificed to obtain a 
product. This definition is congruent with Ahtola’s (1984) argument against 
including monetary price as a lower level attribute in multiattribute models because 
price is a “give” component of the model, rather than a “get” component. Defining 
price as a sacrifice is consistent with conseptualizations by other pricing researchers 
(Chapman 1986; Mazumdar 1986) 
Levels of consumer attention, awareness, and knowledge of prices appear to 
be considerably lower than necessary for consumers to have accurate internal 
reference prices for many products (Dickson and Sawyer 1985). Another recent 
study indicates that price awareness differs among demographic groups, the greatest 
levels of awareness being in consumers who are female, married, older, and do not 
work outside the home (Zeithaml and Berry 1987). Attention to prices is likely to be 
greater for higher priced packaged goods, durable goods, and services than for low 
priced, but other factors in the categories –complexity, lack of price information, 
and processing time required- may interfere with accurate knowledge of prices. An 
additional factor contributing to the gap between actual and perceived price is price 
dispersion, the tendency for the same brands to be priced differently across stores or 
for products of the same type and quality to have wide price variance (Maynes and 
Assum 1982) 
Full price models in economics (e.g. Becker 1965) acknowledge that 
monetary price is not only sacrifice consumers make to obtain products. Time costs, 
search cost, and physic costs all enter either explicitly or implicitly into the 
consumer’s perception of sacrifice. If consumers cannot find products on the shelf, 
or if they must travel distances to buy them, a sacrifice has been made. If consumers 
must expend effort to assemble durable products or time to prepare packaged goods, 
and if this time and effort does not provide satisfaction to the consumer in the form 
of recreation or a hobby, a sacrifice has been made. Research ini economics, home 
economics, and marketing supports the proposition that other costs –time, effort, 
search, psychic-   are salient to consumers (Down 1961; Gronau 1973; Leibowitz 
1974; Leuthold 1981; Linder 1970; Mabry 1970; Mincer 1963) 
 
The Price-Quality Relationship 
Price reliance is a general tendency in some consumers to depend on price as a cue 
to quality (Lambert 1972; Shapiro 1968,1973). The body of literature summarized 
by Olson (1977) is based on the assumption that a general price-perceived quality 
relatinship exists. Despite a multitude of experimental studies on the topic, however, 
the relationship has not surfaced clearly except in situations where methodological 
concerns such as demand artifacts (Sawyer 1975) could offer alternative 
explanations for the results (Monroe and Krishnan 1985; Olson 1977). Monroe and 
Krishnan (1985) concluded that a positive price-perceived quality relationship does 
appear to exist despite the inconsistency of the statistical significance of the research 
findings. They also noted, however, that multiple conceptual problems and 
methodological limitations compromised previous research. 
Many empirical studies have produced results that conflict with Monroe and 
Krishnan’s assessment of a positive relationship. In several studies 9Ftiedman 1967; 
Swan 1974), overall association between price and perceived quality is low. Other 
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studies show the relationship to be nonlinear (Peterson 1970; Peterson and Jolibert 
1976), highly variable across products being judged (Gardner 1971). Other research, 
summarized by Olson (1977), shows that price becomes less important as a quality 
indicator when other product quality cues, such as brand name (Gardner 1971) or 
store image (Stafford and Enis 1969), are present.  
Both Peterson and Wilson (1985) and Olshavsky (1985) argue that the 
emphasis in price-quality syudies should not be on documenting the general price-
perceived qualityrelationship, but on the conditions under which price information is 
likely to lead to an inference about product quality. One possibility is that some 
individuals rely heavily on prices as a quality signal whereas others do not. Peterson 
and Wilson sorted respondents into groups on the basis of their having a price-
reliance schema and confirmed in an experiment that “schematics” perceive a 
stronger relationship between price and quality than “aschematics.” 
Consumers appear to depend more on price as a quality signal in some 
product categories than in others. One explanation for this variation may be 
differences in price-objective quality relationships by category. Another explanation 
may be price variation in a category. Still another category-specific contingency is 
quality variation: in categories where little variation is expected among brands, price 
may function only as an indication of sacrifice whereas in categories where quality 
variation is expected, price may function also as an indication of quality. 
 
The concept of perceived value 
In the means-end chains, value (like quality) is proposed to be a higher level 
abstraction. It differs from quality in two ways. First, value is more individualistic 
and personal than qualityand is therefore a higher level concepts than quality. 
Second, value (unlike quality) involves a tradeoff of give and get components. 
Though many conceptualizations of value have specified quality as the only “get” 
component in the value equation, the consumer may implicitly include other factors, 
several that are in themselves higher level abstractions, such as prestige and 
convenience. 
Consumers sacrifice both money and other resources (e.g. time, energy, 
effort) to obtain products and services. To some consumers, the monetary sacrifice is 
pivotal: some supermarket shoppers will invest hours clipping coupons, raeding 
food advertising in the newspaper, and travelling to different stores to obtain the best 
bargains. To these consumers, anything that reduces the monetary sacrifice will 
increase the perceived value of the product. Less price-conscious consumers will 
find value in store proximity, because time and effort are perceived as more costly. 
How carefully do consumers evaluate these components of products in 
making assessments of value? To judge from the product category of beverages, 
cognitive assessment is limited. Rather tahn carefully considering prices and 
benefits, most respondents depends on cues –often extrinsic cues- in forming 
impressions of value.  These value triggers were present regradless of the way 
consumers defined value. Many consumers who defined value as low price reported 
using a coupon as a signal to low price without actually comparing the reduced price 
of the couponed brand with the prices of the other brands, or they reported that 
“cents-off” or “everyday low prices” signs or aprivate label brand triggered the 
value perception. 
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Holbrook and Corfman (1985) maintain that value perceptions are 
situational and hinge on the context within which an evaluative judgment occurs. 
This view may help explain the diversity of meanings of value. Value meant 
different things at each of these points. At the point of purchase, value often meant 
low price, sale, or coupons. At the point of preparation, value often involved some 
calculation about whether the product was easy to prepare and how much the 
consumer could obtain for what she/he paid.  
As Olshavsky (1985) suggested, not all consumers want to buy the highest 
quality item in every category. Instead, quality appears to be factored into implicit or 
explicit valuation of a product by many consumers (Dodds and Monroe 1985; 
Sawyer and Dickson 1984). A given product may be high quality, but if the 
consumer does not have enaogh money to buy it (or does not want to spend the 
amount required), its value will not be perceived as being as high as that of a 
product with lower quality but a more affordable price. 
 
Objective quality versus perceived quality 
Several reserachers (Dodds and Monroe 1984; Garvin 1983, Holbrook and Corfman 
1985) have emphazised the difference between objective and perceived quality. 
Holbrook and Corfman 91985), for example, distinguish between mechanistic and 
humanistic quality: “....mechanistic [quality] involves an objective aspect or feature 
of a thing or event; humanistic [quality] involves the subjective response of people 
to objects and is therefore a highly relativistic phenomenon that differs betwen 
judges”. “Objective quality” is the term used in the literature (e.g.Hjorth-Anderson 
1984; Monroe and Khrishnan 1985) to describe that actual technical superiority or 
excellence of the products. 
As it has been used in literature, the term “objective quality” refers to 
measurable and verifiable superiority on some predetermined ideal standard or 
standards. Published quality ratings from sources (such as Consumer Reports) are 
used to operationalize the construct of objective quality in research studies (Curry 
and Faulds, 1986).  
The term “objective quality” is related closely to –but not the same as- other 
concepts used to describe technical superiority of a product. For example, Garvin 
(1983) discusses product-based quality and manufacturing-based quality. Product-
based quality refers to amount of specific attributes or ingredients of a product. 
Manufacturing-based quality involves conformance to manufacturing specification 
or service standards. In prevailing Japanese philosophy, quality means “zero defects-
doing it right the first time.” Conformance to requirements 9Crosby 19790 and 
incidence of internal and external failures are other definitions that illustrate 
manufacturing-oriented notions of quality. 
These concepts are not identical to objective quality because they, too, are 
based on perceptions. Though measures of specifications may be actual (rather than 
perceptual), the specifications themselves are set on the basis of what managers 
perceive to be important. Manager’s views many differ considerably from 
consumer’s or user’ view. Consumer Reports ratings may not agree with managers’ 
assesment in term of either salient attributes or weights assigned to the attributes. 
When asked how consumers perceive quality, managers listed workmanship, 
performance, and form as critical components. Consumers actually keyed in on 
different components: appearance, cleanability, and durability.  
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Figure 2. The Perceived Quality Component 
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To reiterate, perceived quality is defined in the model as the consumer’s 
judgement about the superiority or excellence of a product. This perspective is 
similar to the user-based approach of Garvin (1983) and differs from product-based 
and manufacturing-based approaches. Perceived quality is also different from 
objective quality, which arguably may not exist because all quality is perceived by 
someone, be it consumers or managers or researhers at Consumer Reports. 
Lutz (1986) proposes two forms of quality, “affective quality” and 
“cognitive quality”. Affective quality parallels Olshavsky’s and Holbrook and 
Corfman’s views of perceived quality as overall attitude. Cognitive quality is the 
case of a superordinate inferential assessment of quality intervening between lower 
order cues and an eventual overall product evaluation (Lutz 1986). In Lutz’s  view, 
the higher the proportion of attributes that can be assessed before purchase (search 
attributes) to those that can be assessed only during consumption (experience 
attributes), the more likely it is that quality is a higher level cognitive judgement. 
Conversely, as the proportion of experience attributes incerases, quality tends to be 
an affective judgment. Lutz extends this line of reasoning to propose that affective 
quality is relatively more likely for services and consumer nondurable goods (where 
experience attributes dominate) whereas cognitive quality is more likely for 
industrial products and consumer durable goods (where search attributes dominate) 
Evaluation of quality usually take placein comparison context. Maynes (1976) 
claimed that quality evaluations are made within “the set of goods which....would in 
the consumer’s judgement serve the same general purpose for some maximum 
outlay.” A product’s quality is evaluated as high or low depending on its relative 
excellence or superiority among products or services that are viewed as substitutes 
by the consumer. It is critical to note that the specific set of productsused for 
comparison depends on the costumer’s, not firm’s, assessment of competing 
products.  
Holbrook and Corfman (1985) note that early phylosophers used the word 
“quality” to refer to explicit features (i.e. properties of characteristics) of an object 
as perceived by a subject. Olshavsky (1985) terms this tendency to infer quality 
from specific attributes “surrogate-based preference forming behaviour” and cites 
examples of product categories in which a given surrogate is highly associated with 
quality. 
Attributes that signal quality have been dichotomized into intrinsic and 
extrinsic cues (Olson 1977; Olson and Jacoby 1972). Intrinsic cues involve the 
physical composition of the product. Intrinsic attributes cannot be changed without 
altering the nature of the product itself and are consumed as the product is 
consumed. Extrinsic cues are product-related but not part of the physicalproduct 
itself. They are, by definition, outside the product. Price, brand name, and level of 
advertising are example of extrinsic cues to quality. 
The intrinsic-extrinsic dichotomy of quality cues is useful for discussing 
quality but is not without conceptual difficulties. A small number of cues, most 
notably those involving the product’s package, are difficult to classify as either 
intrinsic or an extrinsic. Package could be consideredan intrinsic or an extrinsic cue 
depending on whether the package is part of the physical composition of the product 
(e.g. a dripless spout in detergent or a squeezable ketchup container), in which case 
it would be an intrinsic cue, or protection and promotion for the product (e.g. a 
cardboard container for a computer), in which case it would be an extrinsic cue. For 
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purposes of the model, package is considered an intrinsic cue but the information 
that appears on the package (e.g. brand name, price, logo) is considered an extrinsic 
cue. 
Though the concrete attributes that signal quality differ across products, 
higher level abstract dimensions of quality can be generalized to categories of 
products. As attributes become more abstract (i.e. higher in the means-end chains), 
they become common to more alternatives. Garvin (1987), for example, proposes 
that product quality can be captured in eight dimensions : performance, features, 
reliability, conformance, durability, serviceability, aesthetics, and perceived quality 
(i.e. image). Abstract dimensions that capture diverse specific attributes have been 
discussed have been discussed by Johnson (1983) and Achrol, Reve, and Stern 
(1983). In describing the way consumers compare noncomparable alternatives 9e.g. 
how they choose between such diverse alternatives as a stereo and a Hawaiian 
vacation), Johnson posited that consumers represent that attributes in memory at 
abstract levels (e.g. using entertainment value as the dimension on which to compare 
stereos and Hawaiian vacations). Similarly, Achrol, Reve, and Stern proposed that 
the multitude of specific variables affecting a firm in the environment can be 
captured in abstract dimensions.  
Price, brand name, and level of advertising are three extrinsic cues 
frequently associated with quality in research, yet many other extrinsic cues are 
useful to consumers. Price, the extrinsic cue receiving the most research attention, 
appears to function as a surrogate for quality when the consumer has inadequate 
information about intrinsic attributes. Similarly, brand name serves as a “shorthand” 
for quality by providing consumers with a bundle of information about product 
(Jacoby et al 1978; Jacoby, Szybillo, and Busato-Schach 1977). Level of advertising 
has been related to product quality by economist Nelson (1970,1974), Milgrom and 
Roberts 91986), and Schmalensee (1978). The basic argument holds that for goods 
whose attributes are determined largerly during use (experience goods), higher 
levels of advertising, rather than actual claims made, informs consumer that the 
company believes the goods are worth advertising (i.e. of high quality). Supporting 
this argument is the finding that many subjects in the exploratory study perceived 
heavily advertised brands to be generally higher in quality than brands with less 
advertising. 
Which type of cue –intrinsic or extrinsic- is more important in signaling 
quality to the consumer? An answer to this question would help firms decide 
whether to invest resources in product improvements (intrinsic cues) or in marketing 
(extrinsic cues) to improve perception of quality. Finding a simple and definitive 
answer to this question is unlikely, but the exploratory study suggest the type of 
attribute that dominates depends on several key contingencies. 
The first contingency relates to the point in the purchase decision and 
consumption process at which quality evaluation occurs. Consumer may evaluate 
quality at the point of purchase  (buying a beverage) or at the point of consumption 
(drinking a beverage). The salience of intrinsic attributes at the point of purchase 
depends on whether they can be sensed and evaluated at that time, that is, whether 
they contain search attributes (Nelson 1970). Where search attributes are present, 
they may be important quality indicators. In their absence, consumers depend on 
extrinsic cues. At the point of consumption, most intrinsic attributes can be 
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evaluated and therefore become accessible as quality indicators. Consumers depend 
on intrinsic attributes when the cues have high predictive value (Cox 1962).  
Extrinsic cues are posited to be used as quality indicators when the consumer is 
operating without adequate information about intrinsic product attributes. This 
situation may occur when the consumer : 
• Has little or no experience with the product 
• Has insufficient time or interest to evaluate the intrinsic attributes 
• Cannot readily evaluate the intrinsic attributes 
In other situation, intrinsic product attributes indicating quality are simply too 
difficult for the consumer to evaluate. 
 
Cost Effectiveness and Direct to Consumer Advertising  
Cost effectiveness asks the question: Is the additional health gained from an 
intervention sufficient to justify the societal costs incurred? Gains are often 
measured using some form of a “QALY”, a Quality Adjusted Life Year. Analysts 
calculate the cost per QALY gained, and if that ratio is below a threshold, then the 
treatment is considered “cost effective”, while if it is above, then the treatment is not 
cost effectives. One suggested rule of thumb is that treatments below $50,000 per 
QALY gained are considered very cost effective and treatments below $100,000 per 
QALY gained are cost effective (Ubel et al, 2003).  
To think about the cost effectiveness of DTC advertising, it is necessary to 
frame the question by describing the intervention. We may view the intervention as 
the advertising itself, or as the prescription drug that is consumed in response to the 
advertising. However, in either scenario, the costs calculated and the gains accrued 
will be identical. 
At first blush, the answer to the question of the cost effectiveness of 
prescription drug advertising appears obvious. The cost effectiveness of DTC will be 
a function of the cost effectiveness of the advertised drugs, which are generally well 
established as being cost effective. For example, three of the top ten advertised 
drugs in 2006 were in the class of medications known as “statins”, which are highly 
effective and generally considered to be safe (Shepard et al, 1995). Overall, research 
indicates that targeted statin therapy for the primary prevention of cardiovascular 
events can be cost effective (Pearson, 2000). For example, Glasziou (2003) 
estimated that the discounted long term cost per life year gained for Pravastatin in 
Australia to be $10,938. This includes a 22% reduction in mortality over six years, 
and a 20% decline in hospitalization costs for all vascular events.  
Can these cost effectiveness ratios be applied to individuals who consume 
the drug due to DTC advertising? One obvious difference is the additional cost of 
the advertising itself, which increases costs and may thereby decrease the cost 
effectiveness ratio. However, if the price of the drug does not change, then 
advertising will only reduce the profit per unit for the manufacturer (unless average 
production costs decrease because of increased output), and not change cost 
effectiveness ratio. This argues that if the drug is cost effective, and advertising does 
not affect the price, then the consumption of advertised drugs is necessarily cost 
effective. However, this simple analysis ignores several additional issues that may 
also have an impact.  
From an economic welfare perspective, the desirability of advertising 
depends on the trade-off between potentially increased market prices and reduced 
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search costs. Higher prices will benefit producers at the expense of consumers, while 
reduced search costs will benefit consumers by lowering the true cost of the product 
(Stivers and Tremblay, 2005). Thus the first critical issue is the effect of DTC 
advertising on the price of the advertised drugs. If consumers simply pay more for 
the same drugs or switch from a low priced drug to an equivalent higher priced drug 
(e.g., from a generic to a name brand), then social welfare is not enhanced and the 
cost effectiveness is diminished.  
Second, many observers are concerned that advertising of drugs will lead to 
many patients seeking prescriptions which they may not need (a concern reviewed in 
detail further on in the paper). Normally, economics would argue that, so long as 
consumers are willing to pay the price associated with the visit, this is not a concern. 
The complication is that the visit to the physician’s office is typically paid for by 
insurance, not the patient, so that there is moral hazard in consumption of 
physicians’ services. The drug advertising thus creates a negative externality for the 
insurer (which is often the government) creating economic inefficiencies. From a 
cost effectiveness perspective, the “false positive” visits – visits to the physician 
seeking an inappropriate medication – increase the total cost of the “true positives” 
who appropriately receive the prescription. Thus an increase in visits seeking a 
prescription which is not, after professionalassessment, needed, will result in lower 
cost effectiveness for persons seeking a prescription due to an advertisement they 
viewed than for those diagnosed in more traditional ways.  
Third, there may be a difference in patient characteristics between 
individuals on whom the cost effectiveness ratio was calculated and those seeking 
treatment in response to a prescription drug advertisement. Cost effectiveness ratios 
often depend on the clinical characteristics of the treated population. For example, 
although research indicates that targeted statin therapy for the primary prevention of 
cardiovascular events can be cost effective (Pearson, 2000), the higher the risk of a 
cardiovascular event, the lower the cost per QALY. Thus, because men have a 
higher underlying risk of cardiovascular events, statin therapy for a 58 year-old men 
costs $48,100 per QALY gained but $94,400 per QALY gained for a woman of the 
same age Blake (2003). So if individuals responding to drug advertising are 
systematically different from a more “typical” patient population, then the standard 
cost effectiveness ratios for those patients will also be different. The remainder of 
the paper is organized around these three issues: the impact of advertising on prices, 
the impact on other (non-drug) providers and evidence regarding differences in 
patients who seek treatment due to drug advertising.  
 
The Impact of DTC Prescription Drug Advertising on Prescription Drug 
Prices, Spending and Utilization  
One of the key debates has been the issue of the impact of DTC advertising on drug 
spending. Studies of the question have consistently found that DTC advertising is 
associated with increases in spending on prescription drugs (see Table 4). This is 
true both pre-1997 (Basara, 1996; Stern, 1994) and post-1997 (Gilbody, Wilson and 
Watt, 2005). But the reason for the increase in spending is less clear.  
Prescription drug spending could increase as a result of DTC advertising in 
one of three ways. The advertising could lead to higher prices for advertised drugs; 
it could lead to increased utilization of drugs; finally, it might lead to substitution 
from less expensive to more expensive drugs for the same condition. The 
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implications of these three effects are quite different. If increased spending is due to 
higher prices, then this suggests that the primary impact of DTC advertising is to 
create a more inelastic demand for particular drug products, which is not necessarily 
welfare enhancing. Conversely, if the primary effect is to increase utilization, then 
the welfare impact will be driven by the value of the drug (assuming no selection 
effects). If the effect is caused by substitution to more expensive drugs in a class, 
then the welfare effects will depend on whether any increased benefits of the 
advertised drug relative to the previously utilized drug are cost effective.  
In a 2002 review of the literature, the GAO concluded that the majority of 
the increased spending was due to increased utilization, not due to higher prices 
(GAO, 2002). GAO reports that between 1999 and 2000, utilization for the most 
heavily advertised drugs increased by 25%, while prices rose by 6%. For drugs that 
were not heavily advertised, utilization increased by 4% and prices by 9%. A similar 
finding is reported by Berndt (2001) and in a review by Vogel, Ramachandran and 
Zachry (2002). One contrary finding was reported by Calfee, Winston and Stempski 
(2002), who examined statin use before and after the 1997 change in FDA DTC 
advertising regulations change, and found no evidence that advertising effected 
prescription demand, number of pill, revenues or market shares. However, this study 
linked national data to national prescriptions, rather than using more specific 
market-by-market data.  
This issue is strongly related to the question of whether DTC advertising 
tends to expand market shares for individual products or whether DTC advertising 
expands the overall market for the class of drugs. If DTC advertising expands 
individual product’s market share, at the expense of their competitors, then DTC 
advertising will tend to make the demand for the advertised product less elastic, 
allowing sellers to charge higher prices. The welfare effects of this change would 
depend on the relative merits and prices of the advertised drug and substitutes. 
However, to date, most evidence suggests that DTC advertising expands overall 
market size, rather than individual product market share. Ling, Berndt and Kyle 
(2002) find that DTC advertising for prescription drugs does little for individual 
products’ market share, but instead expands the overall size of the market; this is in 
contrast to the over-the-counter DTC advertising, where the opposite result held. 
Similarly, Donohue and Berndt (2004) report that DTC advertising for 
antidepressants had little impact on drug choice, but increased the probability that an 
individual diagnosed with depression received antidepressant treatment. Both 
studies attribute the lack of impact of DTC advertising on particular drug’s market 
share to the physician acting as the patient’s agent. Berndt et al (1995) found a more 
mixed result in an early (using pre-1997 data) study of H2-antagonists (such as 
Tagamet and Zantac), with DTC advertising effecting both market share and market 
size.  
Bradford et al (2006), in a study of local and national DTC advertising for 
the COX-2 inhibitors Vioxx and Celebrex, found that Vioxx advertisement 
increased Vioxx prescriptions and had a smaller effect on Celebrex prescriptions, 
while Celebrex ads only increased Vioxx prescriptions and had no effect on 
Celebrex sales. This study then is consistent with the idea that that patients respond 
to advertisements and that there is significant spillover between drug 
advertisements. Similarly, Donohue et al (2004) used a commercial claims database 
to show that DTC advertising for depression medications significantly increased the 
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probability of a depression medication being dispensed for those diagnosed with 
depression during an outpatient visit.  
However, Zachry et al (2002) reports that the effect of DTC advertising on 
utilization varies by drug type. DTC advertising had no impact on the number of 
prescriptions written or diagnoses for benign prostatic hypertrophy or 
antihypertensives. For antilipemics (Zocor), every $1000 spent on DTC yielded 32 
new diagnoses and 41 antilipemic prescriptions. Of the 41 antilipemic prescriptions, 
23 were for Zocor.  
Overall, the advertising demand appears to be relatively inelastic. A Kaiser 
Family Foundation study found that every 10% increase in DTC advertising lead to 
a 1% increase in prescription drug spending (Rosenthal, et al, 2003; KFF, 2003). 
The authors estimate that this indicates that every $1 spent on DTC advertising 
yields $4.20 in additional sales. More recently, Iizuka and Jin (2005) find that a $28 
increase in monthly DTC advertising leads to one patient visit within 12 monthsii.  
 
 
Externalities Associated with DTC Advertising  
Physician groups have been very vocal in their opposition to DTC 
advertising of prescription drugs because of concerns about changes in the doctor-
patient relationship and because of fears that advertising may lead to many patients 
seeking unneeded treatments. In contrast, consumers like DTC advertising. Murray 
et al (2004) report that 47% of consumers hold the view that DTC advertising is 
either good or very good and only 19% hold the view that it is bad or very bad 
(Murray et al, 2004). Three quarters of patients think DTC advertising increases 
their awareness of new drugs, and most (58%) felt the ads provided sufficient 
information to allow the consumer to decide whether to discuss the drug with their 
doctor (Aikin, Swasy and Braman, 2004). Women, in particular, felt more in control 
during their visit to the doctor (Murray et al, 2004).  
Despite the official opposition of physician’s groups, individual doctors are 
not as opposed. The FDA found that 41% of doctors believed that DTC advertising 
led to benefits, while 18% believed it led to problems (Aikin, Swasy and Braman, 
2004). 73% of physicians agree or strongly agree that DTC advertising helps 
educate and inform patients, and 67% agree or strongly agree that it helps the 
physician have better discussions with the patient (Weissman et al, 2004). Some 
patients report that doctors acted as if they were being challenged when the patient 
brought up an advertised drug (Murray et al, 2004). However, the FDA found that 
90% of patients reported that doctors welcomed their questions (Aikin, Swasy and 
Braman, 2004).  
This may be because scheduling a visit to a doctor specifically in response 
to a DTC advertisement is rare; the FDA reports that only four percent of patients 
made a visit to a physician with the primary purpose of asking about an advertised 
drug. More commonly, patients asked about an advertised drug during an already 
scheduled visit (Aikin, Swasy and Braman, 2004; Murray et al, 2004). Potential 
patients typically respond to the advertisements by talking to their doctor about the 
advertised drug. Overall, fourteen percent of survey respondents discussed a health 
concern with their doctor as a result of a DTC advertisement. Consumers understand 
that the materials are promotional, and seek their doctor’s advice about the 
appropriateness of particular medications; however, the advertising increases 
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awareness of treatment possibilities (Young et al, 2005). Only six percent of patients 
expected to receive a prescribed medication during a physician visit because of DTC 
advertising (Aikin, Swasy and Braman, 2004). When patients ask for a prescription 
drug they have seen advertised, doctors generally respond by doing something, 
although they often do not prescribe the requested drug. Physicians prescribed the 
DTC advertised drug 39% of the time, a different drug 22% of the time and took no 
action 18% of the time (Weissman et al, 2004).  
Physicians accommodate patients’ requests either because the requested 
drug was the most effective available or is equally effective to other alternatives; 
only 5.5% of the time did physicians prescribe a DTC advertised drug despite 
believing another drug was more effective (Weissman et al, 2004). Doctors 
considered the advertised drug requested by the patient to be a “very likely” choice 
54% of the time (Mintzes et al, 2003). Physicians were more likely to be ambivalent 
about prescribing non-advertised, but requested, prescription drugs than DTC 
advertised drugs requested by patients (Mintzes et al, 2002).  
Advertising tends to focus on drugs that are newer (Donohue et al, 2007) 
and targeted at undertreated illnesses (Iizuka, 2004). The FDA found in surveys that 
among patients who visited a doctor and asked for a prescription drug by brand 
name, 88% had the underlying condition that the prescription drug seeks to treat 
(Rados, 2004). Three-quarters of patients who received a prescribed medication after 
visiting the doctor due to DTC advertising reported feeling much or somewhat better 
overall (Weissman et al, 2003).  
It also appears that DTC advertising may lead to improved quality of care. 
In one of the clearest examples to date, Kravitz et al (2005) found that consumers’ 
asking providers for advertised drugs led to superior care. In a randomized 
controlled trial, only 31% of patients presenting with major depression received 
appropriate depression medications. In contrast, 76% of patients asking for the 
correct medication received appropriate depression medications, while 53% of 
patients who asked for a specific (and appropriate) brand name drug received 
appropriate depression medications. However, Kravitz et al also found that patients 
presenting with symptoms of adjustment disorder with depressed mood, for whom a 
depression medication is not clinically indicated, were also more likely to receive a 
depression prescription if they asked for it.  
 
Selection Effects  
Increased utilization from DTC advertising can occur either by new consumers 
responding to the ad and obtaining prescriptions or by increased usage by those 
patients who already have a prescription – i.e., increased compliance. In either of 
these situations, there is the potential for a selection effect whereby the individuals 
who respond to an advertisement are systematically different from those who do not. 
There is relatively little evidence about the effect of advertising on compliance and 
even less on the selection effects among new patients.  
The most straightforward way that selection could occur is if those who seek 
out drugs in response to DTCA are systematically either more or less severe in their 
illness than the “typical” person who is prescribed the drug. We were unable to 
locate any published articles that examined this question directly, although there is 
much speculation that such selection occurs. This is a fruitful area for further 
research.  
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However, some individuals may not seek out a new drug in response to 
DTCA, but instead may either restart existing prescriptions or adhere better to 
already prescribed drug regimens. Certainly, patient compliance with prescribed 
medications is a significant public health issue. Dezii (2000) found that 70% of 
patients do not comply with their prescribed drug treatments, with an annual societal 
cost of $170 billion, which exceeds total drug expenditures. More than one in ten 
hospital admissions have been blamed on noncompliance (Col, Fanale and 
Kronholm, 1990) as well as 125,000 cardiovascular deaths per year (Sullivan, Krelig 
and Hazlet, 1990). One of the benefits cited for DTCA is improved compliance 
(Armantier and Namoro, 2006). If this is the mechanism by which DTCA increases 
demand, then the selection effect becomes dependent on a comparison of patients 
with high and low adherence rates within drug classes affected by DTCA.  
But the evidence regarding the effect of DTCA on compliance is limited and 
mixed. Donohue et al (2004) found no effect of DTC advertising on compliance 
with a four month treatment regimen for depression for the advertised drug, but a 
small effect for the drug class. For statins, Bradford et al (2006) found that patients 
beginning statin therapy (for which this is a clinical need for uninterrupted treatment 
and frequent non compliance (Ellis et al, 2004; Abughosh et al, 2004; Theibaud et 
al, 2007; Pearson et al, 2000)) during months of high DTC advertising were more 
likely to achieve low-density lipoprotein cholesterol blood-level goals after 
treatment. Patients beginning treatment in high advertising months (defined as the 
top quartile of advertising) were 6% more likely to achieve their goals. However, 
that the effect was only significant for those with the least stringent goals. Finally, 
Wosinska (2005) found that advertising prior to the initiation of therapy for 
hyperlipidemic patients leads to higher compliance, perhaps suggesting an 
interaction between patient motivation and advertising. Also, advertising for any 
brand drug increases compliance across the drug class, although the effect size is 
small. 
 
Objective 
The objective of this study is to determine the impact that DTCA has on 
consumerinitiatedmedication changes for the treatment of GERD and SAD. 
 
Methods Instrument Design 
A questionnaire consisting of 68 items was used to collect data on patientperceptions 
of and actions resulting from viewing televised DTCA. The surveyincluded 
questions about what actions consumers took after viewing DTCA, whatinfluence 
DTCA had on their prescription-seeking behaviors, and what responsephysicians 
had to requests from patients for the medications viewed. Questions torespondents 
about DTCA viewed for specific medications and changes in therapywere posed as 
independent events. The survey also had items regarding cost ofprescriptions to the 
consumer, insurance status, number of prescriptions currentlytaking, and 
demographics. Information regarding the impact of DTCA onconsumer-initiated 
requests for medications used to treat GERD and SAD andthe outcomes associated 
with those requests were specifically targeted. GERD andSAD were selected due to 
the significant amount of advertising dollars allocatedby pharmaceutical companies 
to market their medications used to treat thesetwo diseases (Atherly & Rubin, 2008; 
Rosenthal et al., 2002; USGAO, 2002). 
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Medications included in the survey follow: Nexium, Prevacid, and Protonix 
forGERD and Paxil, Prozac, and Zoloft for SAD. Two distractor medications 
wereincluded in the study, Sultin for GERD and Zitsoter for SAD, to establish 
reliabilityand validity of the author-designed instrument, and ‘‘Other’’ also was 
provided as aresponse. A small group of colleagues tested the instrument to solicit 
feedback on thesurvey design and to establish face validity. Changes were made 
based on thatfeedback prior to finalizing the tool. 
 
Study Participants 
The survey was sent to 2,500 e-mail addresses randomly selected from a 
purchasedlist of AOL, Hotmail, MSN, Road Runner, and Yahoo! accounts of 
consumers overthe age of 18 residing in the United States, and information was 
collected for 3months through February 2005. No respondent identifying data was 
collected,and e-mail addresses were blinded to the authors. Study design was 
approvedInfluence on Consumer Behavior 453by the University of Louisiana-
Monroe Institutional Review Board (IRB).Participation in the survey was considered 
providing informed consent perIRB approval. 
 
Statistical Analysis 
Survey responses and change in therapy were summarized using descriptive 
statistics.The data were analyzed utilizing the binomial test with Z approximation, 
frequencycounts, and Crosstabs, using SPSS 13.0 and SAS 8.1. Applying these tests 
to both theGERD and SAD responses for each medication included in the survey 
resulted inthree binomial tests. 
 
Results Subjects 
Of the 2,500 survey recipients, 487 accessed the provided link and returned 
aresponse. Of those responses, 60 surveys were eliminated: 51 due to a greater 
than10% error rate and nine because the respondents resided outside of the United 
States.The remaining 427 validly executed surveys yielded a 17.1% response rate. 
Therespondents were 70.0% female, 83.1% White=non-Hispanic, and 82.4% 
insured.Approximately one-third of those surveyed were between the ages of 18 and 
34,and one-fourth were over the age of 50. When asked about their prescription 
consumption,40.5% of the respondents reported taking no medications, and 
24.6%reported taking a medication for which they had seen a television 
advertisement.Respondents to this survey were broadly reflective of the population 
ofInternet-mediated health seekers in that they are more likely to be female, 
educated,and affluent compared with the general population (Dutta-Bergman, 2004; 
Spooner,Meredith, & Rainie, 2003). 
 
Respondents With GERD 
When asked if they were taking a medication for heartburn, 83 respondents(19.4%) 
answered affirmatively, and when asked to indicate which brand theywere taking, 
participants selected Prevacid (40), Nexium (26), Protonix (9),and Other (8). No 
respondents chose the fictitious product, Sultin. When askedif they had viewed 
DTCA for prescription heartburn medication, an overwhelmingmajority reported 
seeing advertisements (89.5%), and of those who hadviewed televised DTCA, 10% 
reported talking with their doctor about the advertisedmedication. Of those patient-
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initiated conversations, respondents reportedthat almost half resulted in a change of 
therapy. Of note, the terms of thechange were not specified in the survey and may 
have included initiation, deletion,or modification of therapy.  
 
Respondents With SAD 
Of the 34 respondents who stated that they were taking a medication used to 
treatSAD, 58.8% reported using Zoloft, 26.5% reported taking Paxil, and 14.7%454 
N. M. Khanfar, H. H. Polen, and K. A. Clausonreported taking Prozac. No 
respondents chose the fictitious SAD medication(Zitsoter) and no respondents chose 
Other. Almost 80% of those surveyed reportedseeing a television advertisement for 
a medication used to treat SAD, and of those80%, 20 respondents reported 
discussing the advertised product with their physician,which resulted in a change of 
therapy in eight patients. 
 
Discussion 
Television advertising is a proven mechanism for increasing awareness and sales of 
amultitude of products and services, and the pharmaceutical industry has 
aggressivelytapped into this resource (Advertising Age, 2008). Of the 427 
respondents in this survey,an overwhelming majority reported viewing televised 
DTCA for the top brandsof GERD and SAD medications. The question is whether 
the campaigns for thesemedications have been successful in capitalizing on this 
exposure. According to thissmall self-reported study, the answer is yes, especially 
for the GERD products. Whileonly 10% of patients who viewed DTCA for GERD 
medications discussed thoseadvertisements with their physician, almost one-fifth of 
those patient–physicianencounters ended with a change of therapy. While fewer 
SAD patients reported seeingDTCA, the ultimate impact was even greater in this 
patient population. OnceSAD patients were prompted into discussing those 
advertised medications with theirphysician, 40% reported that it resulted in a change 
of therapy.  
This survey instrumentdid not specifically ask if the change of therapy was 
made to the advertisedmedication, but it did demonstrate, as reported in previous 
literature (Mintzeset al., 2002, 2003; Murray et al., 2004; Weissman et al., 2003), 
that DTCA is capableof provoking a change and directly influencing patient 
care.The fictitious medications in this survey were included in order to 
establishreliability and validity of the instrument. While the other medications were 
recognizedby a large number of those surveyed, fewer than 2% of the 
respondentsreported seeing a commercial for the fictitious products, and no 
respondentsreported taking them, thus reinforcing the validity and reliability of the 
responses.Many diseases, especially those that carry a social stigma with them such 
asdepression and impotence, are underdiagnosed because of reluctance on the partof 
the patient to discuss these sensitive topics with their physicians, and, accordingto 
research, exposure and demystification of these diseases is a possible advantageof 
DTCA (Calfee, 2007; Donohue, 2006; Kravitz et al., 2005). After 
viewingadvertisements for DTCA medication, especially those that give details on 
diseasesymptomatology, patients are more likely to initiate a discussion that 
potentiallycould lead to an early detection and diagnosis (Calfee, 2007; Findlay, 
2002; Holmer,1999; Mintzes et al., 2003). This study showed that 58 out of 427 
patients initiated aconversation with their physician that they directly attributed to 
Influence on Consumer…                                                                                   Budi... 
 138 
DTCA influence.Whether or not this positively impacts pharmaceutical industry 
profits, it is difficultto assign a dollar figure to an improvement in patient outcomes 
and physician–patient communication. The debate continues, however, as to whether 
DTCA helpsor hinders the relationship dynamics between patients and health care 
providers,and further research should be conducted to establish the long-term causal 
relationshipbetween patient-initiated discussions due to DTCA and actualized 
clinicalimprovements in patient outcomes. 
 
Limitations 
The study was limited to the mainland borders of the United States and to 
respondentsresiding in the United States and thus cannot be extrapolated to 
consumerpopulations in New Zealand or in the European Union where regulations 
aboutDTCA are being reconsidered. Additionally, this survey was not designed to 
detectif consumer-initiated changes in therapy were made to the advertised 
medication oranother agent. Finally, this study was unable to measure what disease-
specific orsocioeconomic factors lead to exposure to DTCA being greater in one 
group(GERD), but yielding greater medication change in the other (SAD). 
 
Conclusion 
Based on this small self-reported sample, DTCA via television for medicationsused 
to treat GERD and SAD can have a significant impact on both patient-
initiatedprescription requests and physician prescribing practices and may result in a 
changeof therapy for these diseases. 
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